As China’s central bank continues to implement stimulus measures, Chinese equities have shown resilience with the Shanghai Composite Index and CSI 300 both posting gains. In this environment, identifying undervalued stocks can be a strategic move for investors seeking potential opportunities in a market buoyed by supportive monetary policies.
|
Name |
Current Price |
Fair Value (Est) |
Discount (Est) |
|
Shenzhen Lifotronic Technology (SHSE:688389) |
CN¥16.35 |
CN¥31.74 |
48.5% |
|
Dongfang Electronics (SZSE:000682) |
CN¥11.41 |
CN¥21.35 |
46.6% |
|
Range Intelligent Computing Technology Group (SZSE:300442) |
CN¥32.82 |
CN¥58.97 |
44.3% |
|
Beijing Konruns PharmaceuticalLtd (SHSE:603590) |
CN¥24.09 |
CN¥46.03 |
47.7% |
|
Anhui Huaheng Biotechnology (SHSE:688639) |
CN¥38.83 |
CN¥73.81 |
47.4% |
|
Guangdong Skychem Technology (SHSE:688603) |
CN¥85.80 |
CN¥170.47 |
49.7% |
|
Lancy (SZSE:002612) |
CN¥15.84 |
CN¥28.46 |
44.3% |
|
Guangdong Fenghua Advanced Technology (Holding) (SZSE:000636) |
CN¥16.48 |
CN¥32.10 |
48.7% |
|
Yangmei ChemicalLtd (SHSE:600691) |
CN¥2.21 |
CN¥4.10 |
46.1% |
|
Jiangsu Chuanzhiboke Education Technology (SZSE:003032) |
CN¥10.38 |
CN¥19.22 |
46% |
Here’s a peek at a few of the choices from the screener.
Overview: Sunstone Development Co., Ltd. focuses on the research, development, production, and sales of prebaked carbon anodes for the aluminum industry both in China and internationally, with a market capitalization of CN¥7.92 billion.
Operations: The company generates revenue primarily from the research, development, production, and sales of prebaked carbon anodes for the aluminum industry in both domestic and international markets.
Estimated Discount To Fair Value: 32.7%
Sunstone Development Co., Ltd. is trading at CNY 14.65, significantly below its estimated fair value of CNY 21.76, suggesting it may be undervalued based on cash flows. Despite a decline in sales to CNY 9,919.19 million for the nine months ending September 2024, the company turned a net income of CNY 216.61 million from a previous loss and is forecasted to grow earnings by over 80% annually and revenue by 23.6%, outpacing the market average.
Overview: Shandong Weigao Orthopaedic Device Co., Ltd. operates in the medical device industry, focusing on orthopaedic products, with a market cap of approximately CN¥12.05 billion.
